ESR1 and breast carcinoma: Miller et al. [45] identified a novel miR signature associated with hyperactive MAPK signaling that was significantly correlated with a poor response to hormone therapy in both luminal A and B estrogen receptor (ER)-positive breast cancer subtypes.